View Past PerformanceThis company has been acquiredThe company may no longer be operating, as it has been acquired. Find out why through their latest events.See Latest EventsMarrone Bio Innovations バランスシートの健全性財務の健全性 基準チェック /26主要情報139.35%負債資本比率US$31.87m負債インタレスト・カバレッジ・レシオn/a現金US$9.36mエクイティUS$22.87m負債合計US$53.34m総資産US$76.21m財務の健全性に関する最新情報分析記事 • Mar 13Is Marrone Bio Innovations (NASDAQ:MBII) Using Too Much Debt?Warren Buffett famously said, 'Volatility is far from synonymous with risk.' So it might be obvious that you need to...分析記事 • Dec 09Does Marrone Bio Innovations (NASDAQ:MBII) Have A Healthy Balance Sheet?Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...すべての更新を表示Recent updatesSeeking Alpha • Jul 11Marrone Bio Innovations shareholders approve merger deal with Bioceres Crop SolutionsMarrone Bio Innovations (NASDAQ:MBII) on Monday said its shareholders had approved the proposed merger agreement with Bioceres Crop Solutions (BIOX). BIOX and MBII announced the proposed deal in March, as per which BIOX would acquire MBII in an all-stock transaction. The companies had said that each MBII share will be exchanged at closing for BIOX shares at a fixed ratio of 0.088, representing a value of ~$236M. MBII on Monday said its shareholders met at a special shareholder meeting on July 8 and approved the proposal. MBII said the companies intend to close the deal on July 12. MBII stock -2.4% at $1.03 in morning trading, while BIOX was down 1.5% at $12.04.Reported Earnings • May 13First quarter 2022 earnings: EPS and revenues miss analyst expectationsFirst quarter 2022 results: US$0.042 loss per share (down from US$0.019 loss in 1Q 2021). Revenue: US$11.1m (flat on 1Q 2021). Net loss: US$7.60m (loss widened 133% from 1Q 2021). Revenue missed analyst estimates by 13%. Earnings per share (EPS) also missed analyst estimates by 140%. Over the next year, revenue is forecast to grow 35%, compared to a 12% growth forecast for the industry in the US. Over the last 3 years on average, earnings per share has increased by 33% per year but the company’s share price has fallen by 19% per year, which means it is significantly lagging earnings.Price Target Changed • Apr 27Price target decreased to US$1.38Down from US$2.28, the current price target is an average from 2 analysts. New target price is 61% above last closing price of US$0.85. The company is forecast to post a net loss per share of US$0.058 next year compared to a net loss per share of US$0.095 last year.Breakeven Date Change • Apr 27No longer forecast to breakevenThe 2 analysts covering Marrone Bio Innovations no longer expect the company to break even during the foreseeable future. The company was expected to make a profit of US$886.0k in 2023. New consensus forecast suggests the company will make a loss of US$4.10m in 2023.Reported Earnings • Mar 29Full year 2021 earnings: EPS in line with analyst expectations despite revenue beatFull year 2021 results: US$0.095 loss per share (up from US$0.14 loss in FY 2020). Revenue: US$44.3m (up 16% from FY 2020). Net loss: US$16.6m (loss narrowed 18% from FY 2020). Revenue exceeded analyst estimates by 1.3%. Earnings per share (EPS) were mostly in line with analyst estimates. Over the next year, revenue is forecast to grow 27%, compared to a 13% growth forecast for the industry in the US. Over the last 3 years on average, earnings per share has increased by 28% per year but the company’s share price has fallen by 11% per year, which means it is significantly lagging earnings.Price Target Changed • Mar 18Price target decreased to US$2.14Down from US$2.43, the current price target is an average from 5 analysts. New target price is 104% above last closing price of US$1.05. Stock is down 55% over the past year. The company is forecast to post a net loss per share of US$0.092 next year compared to a net loss per share of US$0.14 last year.Price Target Changed • Jan 19Price target decreased to US$2.28Down from US$2.53, the current price target is an average from 5 analysts. New target price is 211% above last closing price of US$0.73. Stock is down 55% over the past year. The company is forecast to post a net loss per share of US$0.094 next year compared to a net loss per share of US$0.14 last year.Breakeven Date Change • Nov 25No longer forecast to breakevenThe 6 analysts covering Marrone Bio Innovations no longer expect the company to break even during the foreseeable future. The company was expected to make a profit of US$886.0k in 2023. New consensus forecast suggests the company will make a loss of US$3.96m in 2023.Reported Earnings • Nov 12Third quarter 2021 earnings released: US$0.028 loss per share (vs US$0.04 loss in 3Q 2020)The company reported a solid third quarter result with reduced losses, improved revenues and improved control over expenses. Third quarter 2021 results: Revenue: US$9.86m (up 12% from 3Q 2020). Net loss: US$4.95m (loss narrowed 18% from 3Q 2020). Over the last 3 years on average, earnings per share has increased by 24% per year but the company’s share price has fallen by 15% per year, which means it is significantly lagging earnings.Executive Departure • Sep 09Chief Manufacturing Officer Kevin Hammill has left the companyOn the 6th of September, Kevin Hammill's tenure as Chief Manufacturing Officer ended after 3.3 years in the role. As of June 2021, Kevin still personally held 207.90k shares (US$345k worth at the time). A total of 2 executives have left over the last 12 months. The current median tenure of the management team is 3.33 years.分析記事 • Aug 21Time To Worry? Analysts Are Downgrading Their Marrone Bio Innovations, Inc. (NASDAQ:MBII) OutlookThe latest analyst coverage could presage a bad day for Marrone Bio Innovations, Inc. ( NASDAQ:MBII ), with the...Reported Earnings • Aug 18Second quarter 2021 earnings released: US$0.017 loss per share (vs US$0.019 loss in 2Q 2020)The company reported a soft second quarter result with increased losses and weaker control over costs, although revenues improved. Second quarter 2021 results: Revenue: US$12.6m (up 3.4% from 2Q 2020). Net loss: US$3.04m (loss widened 5.7% from 2Q 2020). Over the last 3 years on average, earnings per share has increased by 27% per year but the company’s share price has fallen by 16% per year, which means it is significantly lagging earnings.Price Target Changed • Aug 18Price target decreased to US$2.83Down from US$3.23, the current price target is an average from 5 analysts. New target price is 160% above last closing price of US$1.09. Stock is down 24% over the past year.Reported Earnings • May 15First quarter 2021 earnings released: US$0.019 loss per share (vs US$0.05 loss in 1Q 2020)The company reported a solid first quarter result with reduced losses, improved revenues and improved control over expenses. First quarter 2021 results: Revenue: US$11.0m (up 14% from 1Q 2020). Net loss: US$3.26m (loss narrowed 54% from 1Q 2020). Over the last 3 years on average, earnings per share has increased by 37% per year but the company’s share price has fallen by 7% per year, which means it is significantly lagging earnings.Price Target Changed • Apr 27Price target increased to US$3.29Up from US$2.87, the current price target is an average from 5 analysts. New target price is 82% above last closing price of US$1.81. Stock is up 150% over the past year.分析記事 • Apr 08Marrone Bio Innovations, Inc. (NASDAQ:MBII) Is Expected To Breakeven In The Near FutureMarrone Bio Innovations, Inc. ( NASDAQ:MBII ) is possibly approaching a major achievement in its business, so we would...Reported Earnings • Mar 26Full year 2020 earnings released: US$0.14 loss per share (vs US$0.32 loss in FY 2019)The company reported a solid full year result with reduced losses, improved revenues and improved control over expenses. Full year 2020 results: Revenue: US$38.4m (up 31% from FY 2019). Net loss: US$20.2m (loss narrowed 46% from FY 2019). Over the last 3 years on average, earnings per share has increased by 52% per year but the company’s share price has only increased by 3% per year, which means it is significantly lagging earnings growth.分析記事 • Mar 13Is Marrone Bio Innovations (NASDAQ:MBII) Using Too Much Debt?Warren Buffett famously said, 'Volatility is far from synonymous with risk.' So it might be obvious that you need to...Executive Departure • Feb 24President & CFO James Boyd has left the companyOn the 18th of February, James Boyd's tenure as President & CFO ended after 3.5 years in the role. As of December 2020, James personally held 109.29k shares (US$137k worth at the time). A total of 2 executives have left over the last 12 months.Executive Departure • Feb 19President & CFO James Boyd has left the companyOn the 18th of February, James Boyd's tenure as President & CFO ended after 3.5 years in the role. As of December 2020, James personally held 109.29k shares (US$137k worth at the time). A total of 2 executives have left over the last 12 months.分析記事 • Feb 15What Kind Of Investors Own Most Of Marrone Bio Innovations, Inc. (NASDAQ:MBII)?Every investor in Marrone Bio Innovations, Inc. ( NASDAQ:MBII ) should be aware of the most powerful shareholder...Price Target Changed • Feb 13Price target raised to US$2.32Up from US$2.01, the current price target is an average from 6 analysts. The new target price is 13% below the current share price of US$2.65. As of last close, the stock is up 115% over the past year.Is New 90 Day High Low • Feb 03New 90-day high: US$1.73The company is up 49% from its price of US$1.16 on 04 November 2020. The American market is up 16% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Chemicals industry, which is up 12% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is US$2.90 per share.分析記事 • Jan 25Marrone Bio Innovations (NASDAQ:MBII) Shareholders Have Enjoyed A 75% Share Price GainWhen you buy and hold a stock for the long term, you definitely want it to provide a positive return. But more than...Is New 90 Day High Low • Jan 16New 90-day high: US$1.53The company is up 33% from its price of US$1.15 on 16 October 2020. The American market is up 12% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Chemicals industry, which is up 18% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is US$2.84 per share.分析記事 • Jan 04When Will Marrone Bio Innovations, Inc. (NASDAQ:MBII) Turn A Profit?We feel now is a pretty good time to analyse Marrone Bio Innovations, Inc.'s ( NASDAQ:MBII ) business as it appears the...Is New 90 Day High Low • Dec 11New 90-day high: US$1.34The company is up 18% from its price of US$1.14 on 11 September 2020. The American market is up 13% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Chemicals industry, which is up 10.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is US$8.10 per share.分析記事 • Dec 09Does Marrone Bio Innovations (NASDAQ:MBII) Have A Healthy Balance Sheet?Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...Analyst Estimate Surprise Post Earnings • Nov 11Earnings beat expectations, revenue disappointsRevenue missed analyst estimates by 15%. Earnings per share (EPS) exceeded analyst estimates by 41%. Over the next year, revenue is forecast to grow 47%, compared to a 3.3% growth forecast for the Chemicals industry in the US.Reported Earnings • Nov 11Third quarter 2020 earnings released: US$0.04 loss per shareThe company reported a solid third quarter result with reduced losses and improved revenues and control over expenses. Third quarter 2020 results: Revenue: US$8.83m (up 27% from 3Q 2019). Net loss: US$6.06m (loss narrowed 63% from 3Q 2019). Over the last 3 years on average, earnings per share has increased by 59% per year but the company’s share price has only increased by 2% per year, which means it is significantly lagging earnings growth.財務状況分析短期負債: MBIIの 短期資産 ( $33.0M ) は 短期負債 ( $41.7M ) をカバーしていません。長期負債: MBIIの短期資産 ( $33.0M ) が 長期負債 ( $11.6M ) を上回っています。デット・ツー・エクイティの歴史と分析負債レベル: MBIIの 純負債対資本比率 ( 98.4% ) は 高い と見なされます。負債の削減: MBIIは 5 年前には株主資本がマイナスでしたが、現在はプラスになっており、改善されています。貸借対照表キャッシュ・ランウェイ分析過去に平均して赤字であった企業については、少なくとも1年間のキャッシュ・ランウェイがあるかどうかを評価する。安定したキャッシュランウェイ: MBIIは、現在の フリーキャッシュフロー に基づくと、キャッシュランウェイ が 1 年未満です。キャッシュランウェイの予測: フリーキャッシュフローが毎年11.3 % の歴史的率で成長し続ける場合、 MBIIのキャッシュランウェイは 1 年未満になります。健全な企業の発掘7D1Y7D1Y7D1YMaterials 業界の健全な企業。View Dividend企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2022/07/13 00:02終値2022/07/12 00:00収益2022/03/31年間収益2021/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレークこのレポートを生成するために使用した分析モデルの詳細は、当社の Github ページ でご覧いただけます。また、レポートの使い方に関する ガイド や YouTube の チュートリアル もご用意しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Marrone Bio Innovations, Inc. 3 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。9 アナリスト機関Nathan WeinsteinAegis Capital CorporationBenjamin KalloBairdRobert BurlesonCanaccord Genuity6 その他のアナリストを表示
分析記事 • Mar 13Is Marrone Bio Innovations (NASDAQ:MBII) Using Too Much Debt?Warren Buffett famously said, 'Volatility is far from synonymous with risk.' So it might be obvious that you need to...
分析記事 • Dec 09Does Marrone Bio Innovations (NASDAQ:MBII) Have A Healthy Balance Sheet?Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...
Seeking Alpha • Jul 11Marrone Bio Innovations shareholders approve merger deal with Bioceres Crop SolutionsMarrone Bio Innovations (NASDAQ:MBII) on Monday said its shareholders had approved the proposed merger agreement with Bioceres Crop Solutions (BIOX). BIOX and MBII announced the proposed deal in March, as per which BIOX would acquire MBII in an all-stock transaction. The companies had said that each MBII share will be exchanged at closing for BIOX shares at a fixed ratio of 0.088, representing a value of ~$236M. MBII on Monday said its shareholders met at a special shareholder meeting on July 8 and approved the proposal. MBII said the companies intend to close the deal on July 12. MBII stock -2.4% at $1.03 in morning trading, while BIOX was down 1.5% at $12.04.
Reported Earnings • May 13First quarter 2022 earnings: EPS and revenues miss analyst expectationsFirst quarter 2022 results: US$0.042 loss per share (down from US$0.019 loss in 1Q 2021). Revenue: US$11.1m (flat on 1Q 2021). Net loss: US$7.60m (loss widened 133% from 1Q 2021). Revenue missed analyst estimates by 13%. Earnings per share (EPS) also missed analyst estimates by 140%. Over the next year, revenue is forecast to grow 35%, compared to a 12% growth forecast for the industry in the US. Over the last 3 years on average, earnings per share has increased by 33% per year but the company’s share price has fallen by 19% per year, which means it is significantly lagging earnings.
Price Target Changed • Apr 27Price target decreased to US$1.38Down from US$2.28, the current price target is an average from 2 analysts. New target price is 61% above last closing price of US$0.85. The company is forecast to post a net loss per share of US$0.058 next year compared to a net loss per share of US$0.095 last year.
Breakeven Date Change • Apr 27No longer forecast to breakevenThe 2 analysts covering Marrone Bio Innovations no longer expect the company to break even during the foreseeable future. The company was expected to make a profit of US$886.0k in 2023. New consensus forecast suggests the company will make a loss of US$4.10m in 2023.
Reported Earnings • Mar 29Full year 2021 earnings: EPS in line with analyst expectations despite revenue beatFull year 2021 results: US$0.095 loss per share (up from US$0.14 loss in FY 2020). Revenue: US$44.3m (up 16% from FY 2020). Net loss: US$16.6m (loss narrowed 18% from FY 2020). Revenue exceeded analyst estimates by 1.3%. Earnings per share (EPS) were mostly in line with analyst estimates. Over the next year, revenue is forecast to grow 27%, compared to a 13% growth forecast for the industry in the US. Over the last 3 years on average, earnings per share has increased by 28% per year but the company’s share price has fallen by 11% per year, which means it is significantly lagging earnings.
Price Target Changed • Mar 18Price target decreased to US$2.14Down from US$2.43, the current price target is an average from 5 analysts. New target price is 104% above last closing price of US$1.05. Stock is down 55% over the past year. The company is forecast to post a net loss per share of US$0.092 next year compared to a net loss per share of US$0.14 last year.
Price Target Changed • Jan 19Price target decreased to US$2.28Down from US$2.53, the current price target is an average from 5 analysts. New target price is 211% above last closing price of US$0.73. Stock is down 55% over the past year. The company is forecast to post a net loss per share of US$0.094 next year compared to a net loss per share of US$0.14 last year.
Breakeven Date Change • Nov 25No longer forecast to breakevenThe 6 analysts covering Marrone Bio Innovations no longer expect the company to break even during the foreseeable future. The company was expected to make a profit of US$886.0k in 2023. New consensus forecast suggests the company will make a loss of US$3.96m in 2023.
Reported Earnings • Nov 12Third quarter 2021 earnings released: US$0.028 loss per share (vs US$0.04 loss in 3Q 2020)The company reported a solid third quarter result with reduced losses, improved revenues and improved control over expenses. Third quarter 2021 results: Revenue: US$9.86m (up 12% from 3Q 2020). Net loss: US$4.95m (loss narrowed 18% from 3Q 2020). Over the last 3 years on average, earnings per share has increased by 24% per year but the company’s share price has fallen by 15% per year, which means it is significantly lagging earnings.
Executive Departure • Sep 09Chief Manufacturing Officer Kevin Hammill has left the companyOn the 6th of September, Kevin Hammill's tenure as Chief Manufacturing Officer ended after 3.3 years in the role. As of June 2021, Kevin still personally held 207.90k shares (US$345k worth at the time). A total of 2 executives have left over the last 12 months. The current median tenure of the management team is 3.33 years.
分析記事 • Aug 21Time To Worry? Analysts Are Downgrading Their Marrone Bio Innovations, Inc. (NASDAQ:MBII) OutlookThe latest analyst coverage could presage a bad day for Marrone Bio Innovations, Inc. ( NASDAQ:MBII ), with the...
Reported Earnings • Aug 18Second quarter 2021 earnings released: US$0.017 loss per share (vs US$0.019 loss in 2Q 2020)The company reported a soft second quarter result with increased losses and weaker control over costs, although revenues improved. Second quarter 2021 results: Revenue: US$12.6m (up 3.4% from 2Q 2020). Net loss: US$3.04m (loss widened 5.7% from 2Q 2020). Over the last 3 years on average, earnings per share has increased by 27% per year but the company’s share price has fallen by 16% per year, which means it is significantly lagging earnings.
Price Target Changed • Aug 18Price target decreased to US$2.83Down from US$3.23, the current price target is an average from 5 analysts. New target price is 160% above last closing price of US$1.09. Stock is down 24% over the past year.
Reported Earnings • May 15First quarter 2021 earnings released: US$0.019 loss per share (vs US$0.05 loss in 1Q 2020)The company reported a solid first quarter result with reduced losses, improved revenues and improved control over expenses. First quarter 2021 results: Revenue: US$11.0m (up 14% from 1Q 2020). Net loss: US$3.26m (loss narrowed 54% from 1Q 2020). Over the last 3 years on average, earnings per share has increased by 37% per year but the company’s share price has fallen by 7% per year, which means it is significantly lagging earnings.
Price Target Changed • Apr 27Price target increased to US$3.29Up from US$2.87, the current price target is an average from 5 analysts. New target price is 82% above last closing price of US$1.81. Stock is up 150% over the past year.
分析記事 • Apr 08Marrone Bio Innovations, Inc. (NASDAQ:MBII) Is Expected To Breakeven In The Near FutureMarrone Bio Innovations, Inc. ( NASDAQ:MBII ) is possibly approaching a major achievement in its business, so we would...
Reported Earnings • Mar 26Full year 2020 earnings released: US$0.14 loss per share (vs US$0.32 loss in FY 2019)The company reported a solid full year result with reduced losses, improved revenues and improved control over expenses. Full year 2020 results: Revenue: US$38.4m (up 31% from FY 2019). Net loss: US$20.2m (loss narrowed 46% from FY 2019). Over the last 3 years on average, earnings per share has increased by 52% per year but the company’s share price has only increased by 3% per year, which means it is significantly lagging earnings growth.
分析記事 • Mar 13Is Marrone Bio Innovations (NASDAQ:MBII) Using Too Much Debt?Warren Buffett famously said, 'Volatility is far from synonymous with risk.' So it might be obvious that you need to...
Executive Departure • Feb 24President & CFO James Boyd has left the companyOn the 18th of February, James Boyd's tenure as President & CFO ended after 3.5 years in the role. As of December 2020, James personally held 109.29k shares (US$137k worth at the time). A total of 2 executives have left over the last 12 months.
Executive Departure • Feb 19President & CFO James Boyd has left the companyOn the 18th of February, James Boyd's tenure as President & CFO ended after 3.5 years in the role. As of December 2020, James personally held 109.29k shares (US$137k worth at the time). A total of 2 executives have left over the last 12 months.
分析記事 • Feb 15What Kind Of Investors Own Most Of Marrone Bio Innovations, Inc. (NASDAQ:MBII)?Every investor in Marrone Bio Innovations, Inc. ( NASDAQ:MBII ) should be aware of the most powerful shareholder...
Price Target Changed • Feb 13Price target raised to US$2.32Up from US$2.01, the current price target is an average from 6 analysts. The new target price is 13% below the current share price of US$2.65. As of last close, the stock is up 115% over the past year.
Is New 90 Day High Low • Feb 03New 90-day high: US$1.73The company is up 49% from its price of US$1.16 on 04 November 2020. The American market is up 16% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Chemicals industry, which is up 12% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is US$2.90 per share.
分析記事 • Jan 25Marrone Bio Innovations (NASDAQ:MBII) Shareholders Have Enjoyed A 75% Share Price GainWhen you buy and hold a stock for the long term, you definitely want it to provide a positive return. But more than...
Is New 90 Day High Low • Jan 16New 90-day high: US$1.53The company is up 33% from its price of US$1.15 on 16 October 2020. The American market is up 12% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Chemicals industry, which is up 18% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is US$2.84 per share.
分析記事 • Jan 04When Will Marrone Bio Innovations, Inc. (NASDAQ:MBII) Turn A Profit?We feel now is a pretty good time to analyse Marrone Bio Innovations, Inc.'s ( NASDAQ:MBII ) business as it appears the...
Is New 90 Day High Low • Dec 11New 90-day high: US$1.34The company is up 18% from its price of US$1.14 on 11 September 2020. The American market is up 13% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Chemicals industry, which is up 10.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is US$8.10 per share.
分析記事 • Dec 09Does Marrone Bio Innovations (NASDAQ:MBII) Have A Healthy Balance Sheet?Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...
Analyst Estimate Surprise Post Earnings • Nov 11Earnings beat expectations, revenue disappointsRevenue missed analyst estimates by 15%. Earnings per share (EPS) exceeded analyst estimates by 41%. Over the next year, revenue is forecast to grow 47%, compared to a 3.3% growth forecast for the Chemicals industry in the US.
Reported Earnings • Nov 11Third quarter 2020 earnings released: US$0.04 loss per shareThe company reported a solid third quarter result with reduced losses and improved revenues and control over expenses. Third quarter 2020 results: Revenue: US$8.83m (up 27% from 3Q 2019). Net loss: US$6.06m (loss narrowed 63% from 3Q 2019). Over the last 3 years on average, earnings per share has increased by 59% per year but the company’s share price has only increased by 2% per year, which means it is significantly lagging earnings growth.